Drug
Dotinurad clinical trials
Also written FYU-981.
- studies test it
- 22
- open now
- 5
- in phase 3
- 6
- first study started
- 2013
Keep track of what changes. Save the dotinurad studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- FYU-981
- 11
Combined with it in one product
Studies by the year they started
22 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
- Phase 3
- 6
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Gout
- 9
Who runs them
Industry 20 · Other 2
Fuji Yakuhin Co., Ltd. (9) · Mochida Pharmaceutical Company, Ltd. (5) · Crystalys Therapeutics (3) · Eisai Co., Ltd. (2) · Urica Therapeutics Inc. (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Saga University (1)
Often tested with
Tested in the same studies.
Allopurinol (1) · Oxaprozin (1)
Studies
Open first, then newest update. How each study uses dotinurad is read from its arms, and is right about nine times in ten.
Testing it · 22
- A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout ParticipantsRecruitingPhase 2Crystalys TherapeuticsNCT07535034Written as Dotinurad
- A Study of Dotinurad Versus Allopurinol in Tophaceous GoutRecruitingPhase 3Crystalys TherapeuticsNCT07089888Written as Dotinurad
- A Study of Dotinurad Versus Allopurinol in Participants With GoutRecruitingPhase 3Crystalys TherapeuticsNCT07089875Written as Dotinurad
- The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution TimeNot yet recruitingPhase 4First Affiliated Hospital of Wenzhou Medical UniversityNCT07661030Written as Dotinurad
- Effect of Dotinurad in Hyperuricemia With HypertensionRecruitingPhase 4Saga UniversityNCT06834230Written as Dotinurad
- Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With HyperuricemiaCompletedPhase 1/2Urica Therapeutics Inc.NCT06056570Written as dotinurad
- A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With GoutCompletedPhase 3Eisai Co., Ltd.NCT05007392Written as Dotinurad
- A Single and Multiple Dose Study of Dotinurad in Chinese Healthy ParticipantsCompletedPhase 1Eisai Co., Ltd.NCT05278676Written as Dotinurad
- Drug-drug Interaction Study of FYU-981 and OxaprozinCompletedPhase 1Mochida Pharmaceutical Company, Ltd.NCT03350386Written as FYU-981
- Study of FYU-981 in Hyperuricemia With or Without GoutCompletedPhase 3Fuji Yakuhin Co., Ltd.NCT03006445Written as FYU-981
- Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without GoutCompletedPhase 3Fuji Yakuhin Co., Ltd.NCT03100318Written as FYU-981
- Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)CompletedPhase 1Mochida Pharmaceutical Company, Ltd.NCT03306667Written as FYU-981
- Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without GoutCompletedPhase 3Mochida Pharmaceutical Company, Ltd.NCT03372200Written as FYU-981
- Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)CompletedPhase 1Mochida Pharmaceutical Company, Ltd.NCT03375632Written as FYU-981
- Clinical Pharmacology of FYU-981 (Final Formulation)CompletedPhase 1Mochida Pharmaceutical Company, Ltd.NCT03350373Written as FYU-981
- Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)CompletedPhase 2Fuji Yakuhin Co., Ltd.NCT02515864Written as FYU-981
- Study of FYU-981 in Hyperuricemia With or Without GoutCompletedPhase 2Fuji Yakuhin Co., Ltd.NCT02416167Written as FYU-981
- Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)CompletedPhase 1Fuji Yakuhin Co., Ltd.NCT02347046Written as FYU-981, (Oral single dosing)
- Single Dose Phase I Study of FYU-981CompletedPhase 1Fuji Yakuhin Co., Ltd.NCT02348307Written as FYU-981, (Oral single dosing)
- Repeated Dose Phase I Study of FYU-981CompletedPhase 1Fuji Yakuhin Co., Ltd.NCT02348333Written as FYU-981, (Oral daily dosing for 7 days)
See all 22 studies that test dotinurad →
Given in every arm · 1 — dotinurad is usual care beside what is tested
Codes
What other systems call dotinurad · ClinicalTrials.gg INT001322
- MeSH (NLM) C000706811dotinuradConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 305EB53128DOTINURADConfirmed FDA, NLM, Wikidata
- Wikidata Q97376167dotinuradConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166614DotinuradOne source FDA
- DrugBank DB16145One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706811 | dotinurad | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 305EB53128 | DOTINURAD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q97376167 | dotinurad | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166614 | Dotinurad | One source FDA |
| DrugBank | DB16145 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.